New drugs approved by the FDA are prolonging the lives of those affected.

These drugs reduce production of the abnormal transthyretin protein in the liver, which is responsible for many cases of cardiac amyloidosis. Doctors report that the medications have led to fewer ...

“AL amyloidosis is a fatal disease and systemic therapy is required to prevent deposition of amyloid in other organs and prevent progressive organ failure.” “In this manuscript, we discuss the general ...

Owing to the low incidence of AL amyloidosis, large studies are scarce and hardly any randomized, controlled studies comparing different therapeutic regimens have been conducted. Comparison of studies ...

BERLIN & NAPLES, Fla.--(BUSINESS WIRE)--Bayer, a leading company in key areas of radiology and cardiology, and Attralus, Inc. (Attralus), a clinical stage biopharmaceutical company focused on ...

(Boston) — AL (immunoglobulin light chain) amyloidosis is a rare disease that often results in progressive organ dysfunction, organ failure and eventual death. Clonal plasma cells in the bone marrow ...

Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/KMT2A Rearrangements in a Modern Therapy Era: A Retrospective International Study This retrospective, multicenter study included ...

AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...

Please provide your email address to receive an email when new articles are posted on . “Teclistamab has already been approved in multiple myeloma, and there is institutional data where it shows that ...

Primary (AL) amyloidosis is the most prevalent type of systemic amyloidosis, and management of this disease has evolved through the years from supportive care to aggressive treatments that include ...